SLU-PP-332 is not a peptide in the traditional sense — it's a small synthetic molecule, but it's researched alongside peptides because of what it does: it switches on the same metabolic programmes in your cells that aerobic exercise switches on. The idea of an "exercise pill" has been a goal of metabolic research for decades, and SLU-PP-332 is probably the most compelling candidate to emerge so far.
It works by activating a group of nuclear receptors called ERRs — estrogen-related receptors α, β, and γ — with strongest activity at ERRα. These receptors are master controllers of mitochondrial biogenesis and oxidative metabolism. When you go for a run, your muscles are flooded with signals telling cells to build more mitochondria, burn more fat, and become more efficient at using oxygen. ERRα coordinates a large part of that response. SLU-PP-332 activates it directly, without the run.
In mice, the results were striking. Animals given SLU-PP-332 ran significantly further on a treadmill, had more oxidative muscle fibres, lost fat, and showed improved insulin sensitivity — all without changing their diet or exercise habits. Subsequent research has found effects in the heart (improved function in heart failure models), the kidneys (reduced age-related decline), and fat tissue (reduced obesity in animals fed a high-fat diet).
What hasn't happened yet is any human trial. There is no pharmacokinetic data in humans, no safety data, and no established dose. The 2025 human cell work — which showed reduced oxidative stress in joint tissue — is a very early signal, not clinical evidence. SLU-PP-332 is genuinely exciting science, but it is at an early stage where almost everything that matters for human use remains unknown.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
SLU-PP-332 has compelling preclinical evidence across multiple organ systems showing it replicates key metabolic benefits of aerobic exercise in mice; however, no human clinical trials have been initiated as of early 2026 and there is no human pharmacokinetic, safety, or efficacy data, making this one of the most purely experimental compounds in current research.
the "exercise pill" framing gets a lot of attention but it's worth being precise about what the research actually shows — improved oxidative capacity and fat metabolism, not all the cardiovascular and structural adaptations of real exercise. still an interesting mechanism. the err pathway is well conserved across species which at least makes the mouse-to-human translation slightly less uncertain than usual.
the heart failure finding is the one that stands out to me. most exercise mimetics are primarily about skeletal muscle and fat metabolism, but the cardiac data here points to a broader mitochondrial effect. has anyone seen whether the washington university group is moving toward a clinical programme or licensing it to a pharma company?
this one sits at the very edge of what even counts as research-stage — there's no human pk, no human safety data, no established dose. the mouse results are compelling but the jump from 50 mg/kg ip in mice to a human oral dose is enormous and completely unvalidated. i'd want to see at least a phase 1 safety trial before treating this as anything other than theoretical.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
IGF-1 LR3 is a modified version of IGF-1 — insulin-like growth factor 1 — a hormone your liver produces in res…